Clinical Trial Update: Oral-ATO for TP53-mutated Myeloid Malignancies [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating oral arsenic trioxide for TP53-mutated myeloid malignancies, including acute myeloid leukemia and myelodysplastic syndromes,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• Arsenic Trioxide (arsenic trioxide)

Snippet

Sponsor: The University of Hong Kong | Conditions: Acute Myeloid Leukemia, Myelodysplastic Neoplasm | Phase 2 | Status: RECRUITING